What You Should Know:
- Proscia® a provider of digital and computational pathology solutions, has released study results on new artificial intelligence (AI) that predicts diagnostic agreement for melanoma, the deadliest form of skin cancer.
- The findings, which were presented at the European Conference on Computer Vision (ECCV) 2022, highlight the potential of the technology to improve diagnostic accuracy for melanoma and other diseases with low pathologist concordance.
Findings
Read More
Digital Pathology
Proscia Unveils New Enhancements to its Digital Pathology Platform
What You Should Know:
- Proscia®, a leading provider of digital and computational pathology solutions, has introduced the next version of its Concentriq® Dx platform for primary diagnostic workflows, which is CE-marked under IVDR.
- The release brings together new features and a compelling user experience to help even the largest laboratory networks transition to 100% digital diagnosis. In doing so, they can realize the full promise of the shift away from microscope-based
Read More
KLAS: State of Digital Pathology Among Early Adopters in 2022
What You Should Know:
- In anticipation, many technology vendors are vying for a foothold in the US, leading to a highly varied landscape. In partnership with the Digital Pathology Association (DPA), KLAS surveyed 55 provider organizations (including hospitals, health systems, academic health centers, and reference labs) to assess the state of digital pathology among pioneers in the US and determine which vendors are gaining traction.
- 33 of the interviewed organizations are live with
Read More
KLAS: 7 Key Healthcare Trends in Microsoft Cloud Technologies in 2022
What You Should Know:
- A new report from KLAS focuses on healthcare-specific deployments of Microsoft Cloud Technologies, especially Microsoft Azure, which is receiving strong market interest.
- This study is meant to help organizations considering Microsoft Cloud technologies understand their current use, the overall customer experience, and the impact of the solutions.
Key Healthcare Trends in Microsoft Cloud Technologies in 2022
While still early, healthcare is gaining momentum
Read More
Tribun Health, Mindpeak Partner on AI Diagnostic Tool for Breast Cancer for Pathologists
What You Should Know:
- Tribun Health, the European leader in software development for digital pathology, is pleased to announce a strategic partnership with Mindpeak, a global leader for pathology artificial intelligence (AI) software with world-class industry experts in the development of AI algorithms to provide precision and speed in clinical pathology.
- Together, Tribun Health and Mindpeak help pathologists analyze whole-slide-images (WSI) of immunohistochemically (IHC) stained human
Read More
Proscia Raises $37M for AI-Enabled Pathology Platform
What You Should Know:
- Proscia, a Philadelphia-based provider of digital and computational pathology solutions raises $37M to advance the way we understand and treat diseases like cancer. The round includes participation from Highline Capital Management, Triangle Peak Partners, and Alpha Intelligence Capital as well as existing investors including Scale Venture Partners, Hitachi Ventures, ROBO Global, Emerald Development Managers, and Razor's Edge Ventures. This investment brings Proscia's
Read More
PreciseDx’s AI-Enabled Digital Pathology Proven to Detect Early-Stage Parkinson’s Disease
What You Should Know:
- Mount Sinai spinout, PreciseDx, today announced that its AI-enabled digital pathology is the first proven to detect early-stage Parkinson’s disease, according to a recent research study.
- The study, conducted in collaboration with Michael J. Fox Foundation, identified that PreciseDx’s technology can accurately diagnose Parkinson's disease in living patients prior to the severe onset of symptoms.
Challenges Diagnosing Parkinson’s
Read More
Tempus Launches Pathology-Driven AI Platform
What You Should Know:
- Tempus, a provider of artificial intelligence and precision medicine, today announced the launch of Edge, an innovative platform that allows pathologists to access developing AI models intended to identify specimens with potentially actionable biomarkers using a single hematoxylin and eosin stain (H&E) slide.
- With access to over 50 petabytes of de-identified multimodal data, Tempus is developing AI models with the aim to identify patients who would
Read More
Day 3 HIMSS Roundup: Glooko Acquires DIABNEXT, GE Healthcare/AliveCor Integration
Venture Capital, Private Equity, Mergers & Acquisitions (M&A) Activity
Glooko Acquires DIABNEXT® to Expand Diabetes Offerings in France
Glooko, a leading provider of remote patient monitoring and data management solutions for diabetes and related chronic conditions, today announced the acquisition of DIABNEXT, a Paris-based company whose digital health platform helps people with diabetes better manage their conditions and connects to their healthcare providers, so they can
Read More
Verily & Lumea Partner to Leverage AI in Prostate Cancer Diagnoses
What You Should Know:
- Verily and Lumea today announced a strategic partnership to develop products that can diagnose, prognose, and guide prostate cancer therapy selection with improved objectivity and efficiency.
- Lumea’s integrated digital pathology solution will validate Verily’s AI method for improving cancer detection and grading in partnership with Google Health.
Partnership Goals
The Verily-Lumea collaboration will utilize Lumea’s digital pathology platform
Read More
